Scholar Rock Holding Corp reported a net loss of $322.6 million for the nine months ended September 30, 2026, compared to $287.0 million in the prior year. The company recorded its first product revenue of $0.57 million in Q3 2026, while total liabilities increased significantly to $277.3 million due to new long-term debt financing.
Scholar Rock Holding Divestiture to BioNTech US Inc. for $205M
Scholar Rock agreed to sell its Rare Pediatric Disease Priority Review Voucher (PRV) to BioNTech US Inc. for $205 million in cash. The voucher was originally awarded by the FDA following the approval of ISEMBYLD for the treatment of spinal muscular atrophy. The transaction is subject to customary closing conditions and regulatory clearance under the Hart-Scott-Rodino Act.
Value
$205M
Counterparty
BioNTech US Inc.
“The third quarter was a defining period for Scholar Rock, marked by the FDA approval and U.S. launch of ISEMBYLD, the world’s first and only muscle-targeted therapy for children and adults living with SMA. We are very encouraged by the early ISEMBYLD launch dynamics in the U.S., where the breadth of early demand across SMA treatment centers, physicians, and patients reinforces the significant unmet need in the SMA community.”
David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock
Scholar Rock Holding Director Srinivas Akkaraju Buys $12M of Stock
Srinivas Akkaraju, Director, bought 289,470 shares of Scholar Rock Holding Corp at $41.31 to $41.82 a share (average $41.45) in 6 transactions, worth $12M in total between Oct 23, 2026 and Oct 26, 2026. Shares held after the trade: 723,020 (+15.7%).
Scholar Rock announced that the FDA has approved ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older. The filing also clarifies that the approval includes a post-marketing requirement for a pregnancy safety study and a request for alert reports regarding bone fractures.
Scholar Rock received FDA approval for ISEMBYLD (apitegromab-mstn) for the treatment of spinal muscular atrophy (SMA) in adults and children aged 2 and older. This marks the first and only muscle-targeted treatment approved for SMA, representing a significant therapeutic breakthrough for the company's myostatin biology platform.
Earnings call
Sep 14, 2026, 8:00 AM ET
“Today’s FDA approval of ISEMBYLD marks a defining moment for the SMA community as we now launch the world’s first-ever muscle targeted treatment for children and adults living with SMA in the U.S. After decades of failed industry-wide efforts to unlock the potential of myostatin inhibition, Scholar Rock has delivered a therapeutic breakthrough with ISEMBYLD.”
David L. Hallal, Chairman and Chief Executive Officer of Scholar Rock